Third Rock Ventures
VC Fund
Boston, United States
Third Rock Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
- Total investments:
- 173
- Last investment:
- Lead investor:
- 47%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Third Rock Ventures invests in
Stages Third Rock Ventures invests in
Countries Third Rock Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $19M–$110M
- Series B
- $11M–$190M
- Series C
- $20M–$108M
Investment Focus
Industry
- Biotechnology 63 (36%)
- Health Care 39 (23%)
- Therapeutics 34 (20%)
- Medical 26 (15%)
- Pharmaceutical 17 (10%)
Stage
- Series A 60 (35%)
- Series B 38 (22%)
- Series C 15 (9%)
- Series D 4 (2%)
- Funding Round 4 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cary Pfeffer
Partner
|
Partner | Total investments: 9 | Find email | |
|
Jeff Tong
Partner
|
Partner | Total investments: 2 | Find email | |
Jigar Raythatha
Partner
|
Partner | Total investments: 2 | Find email | |
Mark Levin
Partner
|
Partner | Total investments: 5 | Find email | |
Reid Huber
Partner
|
Partner | Total investments: 12 | Find email | |
| See all 22 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Terremoto Biosciences
|
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M / Series C / Apr 15, 2026 | |
|
Terremoto Biosciences
|
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M / Series C / Apr 15, 2026 | |
Syremis Therapeutics
|
Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M / Series A / Dec 18, 2025 | |
Azalea Therapeutics
|
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M / Series A / Nov 04, 2025 | |
|
Azalea Therapeutics
|
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M / Series A / Nov 04, 2025 | |
|
Azalea Therapeutics
|
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $17M / Seed / Nov 04, 2025 | |
ARTBIO
|
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M / Series B / Jul 29, 2025 | |
Corvia Medical
|
Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M / Jun 17, 2025 | |
| See all 173 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Third Rock Ventures invest in?
Third Rock Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 173 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Third Rock Ventures's check size?
Third Rock Ventures typically joins rounds of $19M–$110M at Series A, $11M–$190M at Series B and $20M–$108M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Third Rock Ventures participates in.
How do I contact Third Rock Ventures?
Public channels for Third Rock Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Third Rock Ventures?
The team at Third Rock Ventures includes Cary Pfeffer (Partner), Jeff Tong (Partner) and Jigar Raythatha (Partner), among 22 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
